58 results
Page 2 of 3
6-K
EX-99.2
xxtbycs so7eh6
5 Nov 21
Current report (foreign)
7:30am
6-K
EX-99.1
pghwkxtxvwcch614
19 Oct 21
Current report (foreign)
7:30am
6-K
EX-99.1
js19sgqcszk48q oklwn
1 Mar 21
Current report (foreign)
12:00am
6-K
EX-5.2
1ew4euljmcpk3s 7d
1 Mar 21
Current report (foreign)
12:00am
424B5
e4bavoac8uoj
26 Feb 21
Prospectus supplement for primary offering
5:10pm
424B5
b52fcq12pdun3p8 2zt
24 Feb 21
Prospectus supplement for primary offering
5:16pm
6-K
u9zouspru9sh8i4ljii8
24 Feb 21
Current report (foreign)
4:16pm
6-K
EX-99.2
thlg8omqfya
11 Jan 21
InflaRx Provides Update on Vilobelimab (IFX-1) Development
7:30am
6-K
EX-99.2
5rveg4p9
29 Oct 20
Current report (foreign)
7:05am
S-8
y1z5rnt
30 Jul 20
Registration of securities for employees
8:39am
6-K
EX-99.2
7j67yc02wj zncn2
30 Jul 20
Current report (foreign)
7:36am
6-K
EX-99.1
nkoto2m sb14ur
30 Jul 20
Current report (foreign)
7:36am
6-K
EX-99.3
jorjoravp
30 Jul 20
Current report (foreign)
7:36am
424B5
dkx08ym xh1o
20 Jul 20
Prospectus supplement for primary offering
9:21am
6-K
EX-99.1
pon173l6x9f7gsta
20 Jul 20
from 6-K
9:02am
F-3/A
ox1owyu rw5ic
16 Jul 20
Shelf registration (foreign) (amended)
9:33am
F-3
pyv2d ccz7w0w51
8 Jul 20
Shelf registration (foreign)
12:00am
F-3
EX-5.2
t7tuorham9f1mztql313
8 Jul 20
Shelf registration (foreign)
12:00am
6-K
6wj9viqlprhdpaa0sj
30 Jun 20
Current report (foreign)
6:38am